Results 281 to 290 of about 814,199 (330)

Impact of Interleukin-1 Blockade on the Development of Macrophage Activation Syndrome in Still Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria. [PDF]

open access: yesArthritis Rheumatol
Erkens RGA   +14 more
europepmc   +1 more source

Nuclear Factor I‐B Delays Liver Fibrosis by Inhibiting Chemokine Ligand 5 Transcription

open access: yesAdvanced Science, EarlyView.
This study identifies the transcription factor Nuclear Factor I‐B (NFIB) as a key suppressor of liver fibrosis. NFIB expression declines during hepatic stellate cell activation, and its overexpression reduces fibrosis in mice models. The mechanism involves NFIB directly repressing chemokine C─C motif ligand 5 (CCL5), thereby alleviating oxidative ...
Qianqian Chen   +14 more
wiley   +1 more source

ETV1 Drives CD4+ T Cell‐Mediated Intestinal Inflammation in Inflammatory Bowel Disease Through Amino Acid Transporter Slc7a5

open access: yesAdvanced Science, EarlyView.
This study identifies the transcription factor ETV1 as a key driver of CD4⁺ T cell‐mediated intestinal inflammation in inflammatory bowel disease (IBD). ETV1 promotes CD4⁺ T cell activation, proliferation, and Th17 differentiation by activating the amino acid transporter SLC7A5, fueling metabolic reprogramming.
Yan Shi   +8 more
wiley   +1 more source

FL/FLT3 signaling enhances mechanical pain hypersensitivity through Interleukin-1 beta (IL-1β) in male mice. [PDF]

open access: yesNeurobiol Pain
Sonrier C   +13 more
europepmc   +1 more source

Precision Editing of NLRS Improves Effector Recognition for Enhanced Disease Resistance

open access: yesAdvanced Science, EarlyView.
Precision engineering of plant NLR immune receptors enables rational design of enhanced pathogen resistance through mismatched pairing, domain swapping, and targeted mutagenesis. These approaches achieve multi‐fold expansion in recognition breadth while minimizing autoimmunity risks and fitness penalties.
Vinit Kumar   +7 more
wiley   +1 more source

Efficacy and Safety of Zabedosertib, an Interleukin-1 Receptor-Associated Kinase 4 Inhibitor, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II Randomized Study. [PDF]

open access: yesDermatol Ther (Heidelb)
Jodl SJ   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy